Arcturus Therapeutics Holdings Inc.

38.86+0.6200+1.62%Vol 375.67K1Y Perf 101.03%
Apr 22nd, 2021 16:00 DELAYED
BID38.01 ASK39.49
Open37.92 Previous Close38.24
Pre-Market- After-Market-
 - -%  - -
Target Price
86.00 
Analyst Rating
Strong Buy 1.25
Potential %
121.31 
Finscreener Ranking
★★★     50.34
Insiders Trans % 3/6/12 mo.
-100/-100/-17 
Value Ranking
★★★+     53.18
Insiders Value % 3/6/12 mo.
-100/-100/-89 
Growth Ranking
★★     48.07
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-80 
Income Ranking
 —    -
Market Cap1.02B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
17.60 
Earnings Date
6th May 2021

Today's Price Range

37.1739.84

52W Range

19.45129.71

5 Year PE Ratio Range

-4.00-2.80

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-3.64%
1 Month
-8.65%
3 Months
-42.60%
6 Months
-21.29%
1 Year
101.03%
3 Years
660.47%
5 Years
18.12%
10 Years
-

TickerPriceChg.Chg.%
ARCT38.860.62001.62
AAPL131.94-1.5600-1.17
GOOG2 267.92-25.3700-1.11
MSFT257.17-3.4100-1.31
XOM55.27-0.7300-1.30
WFC42.70-0.5400-1.25
JNJ165.18-1.4100-0.85
FB296.52-4.9500-1.64
GE13.410.06000.45
JPM147.37-3.1700-2.11
Financial StrengthValueIndustryS&P 500US Markets
9.40
9.40
0.04
0.05
-85.80
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
-
-498.10
-490.70
-222.20
-84.18
RevenueValueIndustryS&P 500US Markets
6.89M
0.26
-10.89
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.90-1.25-38.89
Q03 2020-0.47-0.92-95.74
Q02 2020-0.53-0.55-3.77
Q01 2020-0.49-0.67-36.73
Q04 2019-0.49-0.76-55.10
Q03 2019-0.24-0.56-133.33
Q02 2019-0.53-0.0786.79
Q01 2019-0.44-0.68-54.55
Earnings Per EndEstimateRevision %Trend
3/2021 QR-1.16-152.17Negative
6/2021 QR-1.19-133.33Negative
12/2021 FY-2.79-564.29Negative
12/2022 FY10.9567.18Positive
Next Report Date6th May 2021
Estimated EPS Next Report-1.16
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume375.67K
Shares Outstanding26.28M
Trades Count5.76K
Dollar Volume44.97M
Avg. Volume1.16M
Avg. Weekly Volume457.99K
Avg. Monthly Volume535.35K
Avg. Quarterly Volume817.46K

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock closed at 38.86 per share at the end of the most recent trading day (a 1.62% change compared to the prior day closing price) with a volume of 375.83K shares and market capitalization of 1.02B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 88 people. Arcturus Therapeutics Holdings Inc. CEO is Joseph E. Payne.

The one-year performance of Arcturus Therapeutics Holdings Inc. stock is 101.03%, while year-to-date (YTD) performance is -10.42%. ARCT stock has a five-year performance of 18.12%. Its 52-week range is between 19.45 and 129.71, which gives ARCT stock a 52-week price range ratio of 17.60%

Arcturus Therapeutics Holdings Inc. currently has a PE ratio of -11.50, a price-to-book (PB) ratio of 2.67, a price-to-sale (PS) ratio of 153.76, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.83%, a ROC of -30.89% and a ROE of -34.17%. The company’s profit margin is -84.18%, its EBITDA margin is -490.70%, and its revenue ttm is $6.89 Million , which makes it $0.26 revenue per share.

Of the last four earnings reports from Arcturus Therapeutics Holdings Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.16 for the next earnings report. Arcturus Therapeutics Holdings Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Arcturus Therapeutics Holdings Inc. is Strong Buy (1.25), with a target price of $86, which is +121.31% compared to the current price. The earnings rating for Arcturus Therapeutics Holdings Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arcturus Therapeutics Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arcturus Therapeutics Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 30.85, ATR14 : 4.89, CCI20 : -32.34, Chaikin Money Flow : -0.07, MACD : -7.30, Money Flow Index : 35.47, ROC : -2.07, RSI : 39.61, STOCH (14,3) : 45.69, STOCH RSI : 1.00, UO : 43.92, Williams %R : -54.31), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arcturus Therapeutics Holdings Inc. in the last 12-months were: Andrew H. Sassine (Buy at a value of $148 700), Joseph E. Payne (Buy at a value of $63 380), Keith C. Kummerfeld (Buy at a value of $29 997), Padmanabh Chivukula (Sold 70 000 shares of value $4 155 200 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (87.50 %)
7 (100.00 %)
7 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (12.50 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.00
Strong Buy
1.00

Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-2020.

CEO: Joseph E. Payne

Telephone: +1 858 900-2660

Address: 10628 Science Center Drive, San Diego 92121, CA, US

Number of employees: 88

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

57%43%

Bearish Bullish

57%43%

Bearish Bullish

58%43%

News

Stocktwits